AEON

AEON Biopharma Announces Redemption of Public Warrants

Retrieved on: 
Sunday, March 31, 2024
AEON, Transfer, Common stock, Warrant, Exercise, Common, Sale, Attention, IPO, Fair market value, Redemption, Security (finance)

At the direction of the Company, the Warrant Agent has delivered a notice of redemption to each of the registered holders of the outstanding Public Warrants.

Key Points: 
  • At the direction of the Company, the Warrant Agent has delivered a notice of redemption to each of the registered holders of the outstanding Public Warrants.
  • Any Public Warrants that remain unexercised at 5:00 p.m. New York City time on the Redemption Date will be delisted, void and no longer exercisable, and the holders will have no rights with respect to those Public Warrants, except to receive the Redemption Price (or as otherwise described in the redemption notice for holders who hold their Public Warrants in “street name”).
  • The Redemption Fair Market Value means the volume weighted average price of the Common Stock for the ten trading days immediately following the date of the notice of redemption.
  • Questions concerning redemption and exercise of the Public Warrants can be directed to Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, New York 10004, Attention: Compliance Department, telephone number (212) 509-4000.

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, March 29, 2024
AEON, Steps, U.S. FDA, LTD, Headache, Patient, Migraine, Investment, Alembic Pharmaceuticals, Safety, FDA, Food, Pharmaceutical industry

IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • We are now well-positioned to plan for the initiation of our pivotal Phase 3 program,” commented Marc Forth, AEON’s President and Chief Executive Officer.
  • “Recently, we announced plans to conduct an interim analysis of our ongoing Phase 2 study of ABP-450 as a preventive treatment for chronic migraine, which completed enrollment in December 2023.
  • On track to announce topline results from the Phase 2 study of ABP-450 as a preventive treatment for chronic migraine in the third quarter of 2024.
  • Episodic Migraine Program Next Steps – The Company is continuing to plan for the initiation of its proposed pivotal Phase 3 program for ABP-450.

Ecommerce Innovator Spresso Secures Initial Series A Funding Led by Funds and Accounts Managed by BlackRock

Retrieved on: 
Tuesday, April 9, 2024
Artificial Intelligence, Professional Services, Restaurant, Bar, Office Products, Electronic Commerce, Convenience Store, Catalog, Data Analytics, Software, Other Retail, Wine & Spirits, Data Management, Tobacco, Supply Chain Management, Supermarket, Online Retail, Technology, Specialty, Luxury, Discount, Variety, Department Stores, Food, Beverage, Fashion, Cosmetics, Retail, Spend, AEON, Cloud, Aeon Group, Google Cloud, Algorithm, Growth, BHD, BlackRock, AI, Commerce, Analysis, Snowflake

Spresso , a leading provider of AI-powered solutions for ecommerce businesses, today announced an initial Series A investment from funds and accounts managed by BlackRock (“BlackRock”).

Key Points: 
  • Spresso , a leading provider of AI-powered solutions for ecommerce businesses, today announced an initial Series A investment from funds and accounts managed by BlackRock (“BlackRock”).
  • “BlackRock's investment signifies their continued confidence in our vision,” said Jared Yaman, CEO of Spresso.
  • Commerce Suite : Robust ecommerce platform for building and managing successful online storefronts, ensuring seamless customer experiences.
  • “We are excited to continue to support the company’s growth through this investment.”
    BlackRock first made a strategic investment in Spresso in May 2023.

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Retrieved on: 
Tuesday, March 19, 2024
AEON, MMD, Patent, Caregiver, Headache, Migraine, Patient, Injection, Safety, AB toxin, Phase II, FDA, Food, MHD, Pharmaceutical industry

IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced a productive end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) following the Phase 2 data in episodic migraine previously released in October 2023, that supports advancing ABP-450 (prabotulinumtoxinA) injection into the proposed pivotal Phase 3 program. As part of the updated development plan, the Company will now conduct an interim analysis of the ongoing Phase 2 study of ABP-450 for the preventive treatment of chronic migraine and anticipates releasing the data in the second quarter of 2024.

Key Points: 
  • Patients have at least a one-year history of migraine (with or without aura) according to the ICHD-3 (2018) definition and diagnostic criteria.
  • All patients will receive two treatment cycles 12 weeks apart utilizing the Company’s patented treatment paradigm (U.S. Patent No.
  • 11,826,405) involving fewer injections than the current botulinum toxin treatment option for migraine.
  • The interim analysis will include approximately 100 chronic migraine patients in each of the three arms that have completed the two 12-week treatment cycles.

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Retrieved on: 
Tuesday, March 19, 2024
AEON, Private placement, Private, LTD, FPA, Sale, Migraine, Note, Alembic Pharmaceuticals, AB toxin, Food, FDA, Pharmaceutical industry

IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE AMEX: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced it has entered definitive agreements relating to a private placement (the "Private Placement") of $15 million (the “Investment Amount”) aggregate principal amount of senior secured convertible notes (the "Notes") with Daewoong Pharmaceutical Co., LTD. Proceeds from the Private Placement will be paid in a first installment of $5 million and a second installment of $10 million, in each case subject to the closing conditions set forth in the agreements. The Company expects the first installment to close before the end of March 2024 and the second to close in April 2024. Proceeds from the Private Placement will be used to support the late-stage clinical development of ABP-450 and for general working capital purposes. Upon funding of the second installment of the Investment Amount, the Company will appoint one designee of Daewoong to the AEON Board of Directors, subject to a customary due diligence process by AEON. The Daewoong designee must be a member of Daewoong’s senior management team.

Key Points: 
  • Proceeds from the Private Placement will be paid in a first installment of $5 million and a second installment of $10 million, in each case subject to the closing conditions set forth in the agreements.
  • The Company expects the first installment to close before the end of March 2024 and the second to close in April 2024.
  • Proceeds from the Private Placement will be used to support the late-stage clinical development of ABP-450 and for general working capital purposes.
  • Concurrent with the execution of the agreements for the Private Placement, the Company terminated its forward purchase agreements (each an “FPA” and the counterparties thereto, together, the “FPA Providers”).

China UnionPay Optimizes Payment Services with the Launch of Project Excellence 2024

Retrieved on: 
Monday, March 18, 2024
AEON, LPB, State Council, F&B, OCBC, Growth, Environment, Health, Partnership, Education, Committee, Bank, Lead, UMS, Economic development, Transport, QR, PBOC, City, OEM, Happiness, Tourism, Central China, ATM, Digital divide, Government, Work, Ageing, Cryptocurrency

SHANGHAI, March 18, 2024 /PRNewswire/ -- On March 15, the launch ceremony for Explore China Your Way with UnionPay: China UnionPay Payment Service Optimization - Project Excellence 2024 was held in Shanghai.

Key Points: 
  • SHANGHAI, March 18, 2024 /PRNewswire/ -- On March 15, the launch ceremony for Explore China Your Way with UnionPay: China UnionPay Payment Service Optimization - Project Excellence 2024 was held in Shanghai.
  • In order to fully implement the requirements provided by the guidelines, China UnionPay has taken the initiative to launch Project Excellence 2024 to fully participate in the campaign to improve payment convenience for the senior citizens and international visitors to China.
  • With the goal of delivering full solutions for all use cases across China, Project Excellence 2024 will be jointly implemented and co-funded by industry participants.
  • At the event, UnionPay also signed collaboration agreements with Ctrip Financial Services and China Tourism Group to provide more user-friendly cross-border payment services for international visitors to China.

China UnionPay Optimizes Payment Services with the Launch of Project Excellence 2024

Retrieved on: 
Monday, March 18, 2024
AEON, LPB, State Council, F&B, OCBC, Growth, Environment, Health, Partnership, Education, Committee, Bank, Lead, UMS, Economic development, Transport, QR, PBOC, City, OEM, Happiness, Tourism, Central China, ATM, Digital divide, Government, Work, Ageing, Cryptocurrency

SHANGHAI, March 18, 2024 /PRNewswire/ -- On March 15, the launch ceremony for Explore China Your Way with UnionPay: China UnionPay Payment Service Optimization - Project Excellence 2024 was held in Shanghai.

Key Points: 
  • SHANGHAI, March 18, 2024 /PRNewswire/ -- On March 15, the launch ceremony for Explore China Your Way with UnionPay: China UnionPay Payment Service Optimization - Project Excellence 2024 was held in Shanghai.
  • In order to fully implement the requirements provided by the guidelines, China UnionPay has taken the initiative to launch Project Excellence 2024 to fully participate in the campaign to improve payment convenience for the senior citizens and international visitors to China.
  • With the goal of delivering full solutions for all use cases across China, Project Excellence 2024 will be jointly implemented and co-funded by industry participants.
  • At the event, UnionPay also signed collaboration agreements with Ctrip Financial Services and China Tourism Group to provide more user-friendly cross-border payment services for international visitors to China.

China UnionPay Optimizes Payment Services with the Launch of Project Excellence 2024

Retrieved on: 
Saturday, March 16, 2024
AEON, LPB, State Council, F&B, OCBC, Growth, Environment, Health, Partnership, Education, Committee, Bank, Lead, UMS, Economic development, Transport, QR, PBOC, City, OEM, Happiness, Tourism, Central China, ATM, Digital divide, Government, Work, Ageing, Cryptocurrency

SHANGHAI, March 16, 2024 /PRNewswire/ -- On March 15, the launch ceremony for Explore China Your Way with UnionPay: China UnionPay Payment Service Optimization - Project Excellence 2024 was held in Shanghai.

Key Points: 
  • SHANGHAI, March 16, 2024 /PRNewswire/ -- On March 15, the launch ceremony for Explore China Your Way with UnionPay: China UnionPay Payment Service Optimization - Project Excellence 2024 was held in Shanghai.
  • In order to fully implement the requirements provided by the guidelines, China UnionPay has taken the initiative to launch Project Excellence 2024 to fully participate in the campaign to improve payment convenience for the senior citizens and international visitors to China.
  • With the goal of delivering full solutions for all use cases across China, Project Excellence 2024 will be jointly implemented and co-funded by industry participants.
  • At the event, UnionPay also signed collaboration agreements with Ctrip Financial Services and China Tourism Group to provide more user-friendly cross-border payment services for international visitors to China.

China UnionPay Optimizes Payment Services with the Launch of Project Excellence 2024

Retrieved on: 
Saturday, March 16, 2024
AEON, LPB, State Council, F&B, OCBC, Growth, Environment, Health, Partnership, Education, Committee, Bank, Lead, UMS, Economic development, Transport, QR, PBOC, City, OEM, Happiness, Tourism, Central China, ATM, Digital divide, Government, Work, Ageing, Cryptocurrency

SHANGHAI, March 16, 2024 /PRNewswire/ -- On March 15, the launch ceremony for Explore China Your Way with UnionPay: China UnionPay Payment Service Optimization - Project Excellence 2024 was held in Shanghai.

Key Points: 
  • SHANGHAI, March 16, 2024 /PRNewswire/ -- On March 15, the launch ceremony for Explore China Your Way with UnionPay: China UnionPay Payment Service Optimization - Project Excellence 2024 was held in Shanghai.
  • In order to fully implement the requirements provided by the guidelines, China UnionPay has taken the initiative to launch Project Excellence 2024 to fully participate in the campaign to improve payment convenience for the senior citizens and international visitors to China.
  • With the goal of delivering full solutions for all use cases across China, Project Excellence 2024 will be jointly implemented and co-funded by industry participants.
  • At the event, UnionPay also signed collaboration agreements with Ctrip Financial Services and China Tourism Group to provide more user-friendly cross-border payment services for international visitors to China.

Oasis Enters into an Agreement with AEON for Sale of its Tsuruha Shares

Retrieved on: 
Wednesday, February 28, 2024
Pharmaceutical, Other Retail, Finance, Health, Asset Management, Banking, Professional Services, Retail, AEON, Sale, Aeon

Oasis Management Company Ltd. is the manager to private funds (together with the manager, collectively “Oasis”) that own shares of Tsuruha Holdings Inc. (“Tsuruha” or the “Company”).

Key Points: 
  • Oasis Management Company Ltd. is the manager to private funds (together with the manager, collectively “Oasis”) that own shares of Tsuruha Holdings Inc. (“Tsuruha” or the “Company”).
  • As detailed below, today Oasis has entered into an agreement with AEON Co., Ltd. (“Aeon”) for the sale (the “Sale”) of the approximately 13.6% stake in Tsuruha shares that Oasis owns.
  • Oasis has actively engaged with Tsuruha since 2022 to enhance Tsuruha’s corporate value in accordance with the Japan Stewardship Code.
  • Under these circumstances, Oasis has come to an agreement with Aeon on the Sale of the Tsuruha shares that Oasis owns.